XYRA's New Patent Offers Hope for Patients at Risk of Heart Failure and Strokes XYRA LLC has obtained a new US patent for a treatment aimed at reducing atrial fibrillations, potentially transforming heart failure and stroke risk management.

XYRA's New Patent Offers Hope for Patients at Risk of Heart Failure and Strokes #USA #Atrial_Fibrillation #Los_Altos #Budiodarone #XYRA_LLC

XYRA Secures Fifth US Patent for Budiodarone in Atrial Fibrillation Management Until 2040 XYRA LLC, a biopharmaceutical firm, has announced the issuance of its fifth US patent for budiodarone, aiding in atrial fibrillation management and extending protections until 2040.

XYRA Secures Fifth US Patent for Budiodarone in Atrial Fibrillation Management Until 2040 #United_States #Atrial_Fibrillation #Los_Altos #Budiodarone #XYRA_LLC